39
Participants
Start Date
September 1, 2025
Primary Completion Date
August 31, 2027
Study Completion Date
August 31, 2027
Patients with specific TIME subtype and ALK fusion mutations (confirmed via RNA-seq and OncoKB annotation) will receive tyrosine kinase inhibitors (TKIs, e.g., alectinib or crizotinib) as first-line
Patients with specific TIME subtype and ALK fusion mutations (confirmed via RNA-seq and OncoKB annotation) will receive tyrosine kinase inhibitors (TKIs, e.g., alectinib or crizotinib) as first-line therapy. Clinical response will be assessed via RECIST v1.1 criteria using serial CT imaging (baseline, 8 weeks, and every 12 weeks thereafter). Correlative analyses will evaluate TKI efficacy in relation to TIME subtype, ALK fusion variant, and multi-omic signatures.
RECRUITING
Centre of Translational Medicine, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou
Zhejiang University
OTHER
General Hospital of Ningxia Medical University
OTHER
First People's Hospital of Hangzhou
OTHER